Analyst Research
| Report Title | Price |
|---|---|
|
Trading Report for (VAR). A detailed report, including free correlated market analysis, and updates.
Provider: Stock Traders Daily
|
$58.00
|
|
Provider: Pechala's Reports
|
$15.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Varian Medical Systems Inc. Lowers FY 2012 Revenue Guidance; Adjusts FY 2012 EPS Guidance To A Range Below Analysts' Estimates
Varian Medical Systems Inc. announced that with tremendous movements in currency exchange rates, particularly the substantial weakening of the Euro, it is adjusting outlook for fiscal 2012. Compared with fiscal 2011 totals, the Company now expects revenues could increase by about 8% and net earnings per diluted share from continuing operations could grow by 8% to 9%. The Company reported revenues of $2.597 billion and EPS $3.44 in fiscal 2011. According to I/B/E/S Estimates, analysts are expecting the Company to report revenues of $2.842 billion and EPS of $3.79 for fiscal 2012.
Latest Developments for Varian Medical Systems Inc
- Varian Medical Systems Inc Receives FDA 510(k) Clearance Of Its Nexus DRF Digital X-Ray Imaging System
- Varian Medical Systems Inc Issues Q3 2013 Guidance; EPS Guidance Below Analysts' Estimates; Reaffirms FY 2013 Guidance
- Varian Medical Systems Inc Receives FDA 510(k) Clearance For Edge Radiosurgery Suite For Non-Invasive Surgical Procedures
- Varian Medical Systems Inc Issues Q2 2013 Guidance; Revenue Guidance Below Analysts' Estimates; Reaffirms FY 2013 Revenue Guidance; Raises Low End Of Prior FY 2013 EPS Guidance-Conference Call
Latest Key Developments in Advanced
- Covidien PLC Approves Separation Of Pharmaceuticals Business And Declares Dividend Of Mallinckrodt Ordinary Shares
- Nephros Inc Announces Completion Of Rights Offering
- Volcano Corp Announces Preliminary Results From ADVISE II Study
- Nordion Inc Enters Into Agreement To Divest Targeted Therapies Business To BTG Plc
- Share this
- Link this
- Digg this
Follow Reuters